Brief: Pherecydes Pharma: Benefits Of Phages In Treating Pneumonia (VAP)
08/04/2021 17:50
April 8 (Reuters) - PHERECYDES PHARMA SA ALPHE.PA :
* PRECLINICAL TRIAL DEMONSTRATES THE BENEFITS OF INHALED
PHERECYDES PHARMA PHAGES IN TREATING VENTILATION-ASSOCIATED
PNEUMONIA
* REDUCTION OF THE MORTALITY RATE IN MICE WITH A SINGLE
PULMONARY
DELIVERY COMPARABLE TO THE BENCHMARK ANTIBIOTIC DELIVERED VIA
INTRAVENOUS OR PULMONARY ROUTE
* 99% REDUCTION IN THE PULMONARY BACTERIAL LOAD IN PIGS WHEN
DELIVERED BY INHALATION
* TO INITIATE PHASE I/II CLINICAL DEVELOPMENT IN RESPIRATORY
INDICATIONS WITHIN THE NEXT TWO YEARS
Source text for Eikon: ID:nBw1TGyZTa
Further company coverage: ALPHE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes